Vimarsana
Biggest News Aggregation in the World

Madison Muller News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Madison Muller. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Madison Muller Today - Breaking & Trending Today

Hims launches $199 weight-loss shots at 85% discount to Wegovy - Vimarsana News

Hims launches $199 weight-loss shots at 85% discount to Wegovy

The wildly popular shots are protected by patents until at least 2032.

🔒 Preserving muscle, losing fat is new target for weight-loss drugs - Vimarsana News

🔒 Preserving muscle, losing fat is new target for weight-loss drugs

Weight-loss shots are highly effective, but preserving muscle during fat loss is now a key focus for drugmakers like Regeneron and Eli Lilly.

Investors Pile Into Amgen in Search of Next Obesity Drug Payout - Vimarsana News

Investors Pile Into Amgen in Search of Next Obesity Drug Payout

(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackBuffett Praises Apple After Trimming It, Drops Paramount StakeTreasury Rally Risks Running Into a $125 Billion Brick WallFrance’s Macron Calls for Reset of Economic Ties With ChinaLamborghini Bros No More: Crypto Is Creating a New Wealth EffectThe shares

Source: yahoo.com
Lilly reports earnings, raises forecast | The Arkansas Democrat-Gazette - Vimarsana News

Lilly reports earnings, raises forecast | The Arkansas Democrat-Gazette

Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.

Ozempic Means Junk-Food Makers Need Course Correction - Vimarsana News

Ozempic Means Junk-Food Makers Need Course Correction

(Bloomberg) -- Companies selling unhealthy foods need to tweak their business models to counter the growing popularity of weight-loss drugs — or risk alienating investors, according to the latest Bloomberg Markets Live Pulse survey.Most Read from BloombergLargest Covid Vaccine Study Yet Finds Links to Health ConditionsCapital One to Buy Discover Financial in $35 Billion DealAmazon Deserves to Be Called Out for Swindling UsersWall Street’s Moelis Bet Big on the Middle East. Now He’s Cashing InSto

Source: yahoo.com